Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;91(5):106624.
doi: 10.1016/j.jinf.2025.106624. Epub 2025 Oct 3.

Sustained clinical and epidemiological impact of Respiratory Syncytial Virus (RSV) in young infants exposed to universal immunization with Nirsevimab at birth: An Italian multicenter, retrospective, cohort study 2024/25

Paolo Manzoni  1 , Matteo Riccò  2 , Cecilia Nobili  3 , Chryssoula Tzialla  4 , Graziano Barera  5 , Paolo Del Barba  5 , Simona De Franco  6 , Guido Pellegrini  7 , Paola Magri  7 , Enrico Crapanzano  8 , Giangiacomo Nicolini  9 , Andrea Alba  9 , Stefano Fiocchi  10 , Mauro Vivalda  11 , Giulia Natta  11 , Alessandra Casati  12 , Mariano Manzionna  13 , Simone Rugolotto  14 , Laura Saggioro  14 , Simona Pesce  15 , Maria Scavone  15 , Antonietta Distilo  16 , Vincenza Roseto  17 , Antonino Di Toro  18 , Luca Pierri  18 , Gianfranco Scarpelli  19 , Elvira Bonanno  19 , Lidia Decembrino  20 , Enrico Felici  21 , Camilla Selvatico  21 , Valentina Saracco  21 , Francesco Morrone  22 , Mario Giuffrè  23 ; Italian Collaborative Network for surveillance and management of Neonatal and Infantile Infections (GdSIN)
Affiliations
Free article

Sustained clinical and epidemiological impact of Respiratory Syncytial Virus (RSV) in young infants exposed to universal immunization with Nirsevimab at birth: An Italian multicenter, retrospective, cohort study 2024/25

Paolo Manzoni et al. J Infect. 2025 Nov.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Paolo Manzoni declares speaker fees from Pfizer, Sanofi, AstraZeneca, MSD.

LinkOut - more resources